Moderna’s work developing seasonal vaccines is ‘risky’ under current FDA, analyst says
Strong Bearish
-100.0
The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
